Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OPC-224333
- Development stage
- Unknown
- Lead developer
- Otsuka Holdings
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OPC-224333 is an investigational small molecule drug candidate being developed by Otsuka America Pharmaceuticals for the treatment of epilepsy. As of early 2024, the compound is in Phase 1 clinical development, with studies focusing on evaluating its safety, tolerability, and pharmacokinetic profile in healthy adult participants through single-ascending-dose (SAD) and multiple-ascending-dose (MAD) protocols. While the specific molecular target and mechanism of action have not been publicly disclosed by the developer, OPC-224333 represents a novel addition to Otsuka's central nervous system (CNS) pipeline aimed at addressing unmet needs in seizure management.
Beyond the preview
Go deeper on OPC-224333.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OPC-224333.